Italian results of the PRECONNECT study: safety and efficacy of trifluridine/tipiracil in metastatic colorectal cancer.
colorectal cancer
quality of life
real life
safety
trifluridine/tipiracil
Journal
Future oncology (London, England)
ISSN: 1744-8301
Titre abrégé: Future Oncol
Pays: England
ID NLM: 101256629
Informations de publication
Date de publication:
Jun 2021
Jun 2021
Historique:
pubmed:
6
3
2021
medline:
30
11
2021
entrez:
5
3
2021
Statut:
ppublish
Résumé
The international PRECONNECT Phase IIIb study demonstrated safety and efficacy of trifluridine/tipiracil in the management of patients with metastatic colorectal cancer. Lay abstract PRECONNECT is an international study demonstrating the efficacy and tolerability of the drug combination trifluridine/tipiracil in adult patients with metastatic colorectal cancer treated in everyday clinical practice. For this publication, the authors conducted an analysis performed on the 161 Italian patients enrolled in this study. These kinds of analyses are important because of the differences that may arise across different countries. The most common contraindications were not dangerous to health. Furthermore, 3 months from beginning the medication, half of the patients did not show a worsening of the disease and quality of life during treatment was maintained.
Autres résumés
Type: plain-language-summary
(eng)
Lay abstract PRECONNECT is an international study demonstrating the efficacy and tolerability of the drug combination trifluridine/tipiracil in adult patients with metastatic colorectal cancer treated in everyday clinical practice. For this publication, the authors conducted an analysis performed on the 161 Italian patients enrolled in this study. These kinds of analyses are important because of the differences that may arise across different countries. The most common contraindications were not dangerous to health. Furthermore, 3 months from beginning the medication, half of the patients did not show a worsening of the disease and quality of life during treatment was maintained.
Identifiants
pubmed: 33663264
doi: 10.2217/fon-2020-1278
doi:
Substances chimiques
Drug Combinations
0
Pyrrolidines
0
trifluridine tipiracil drug combination
0
Thymine
QR26YLT7LT
Trifluridine
RMW9V5RW38
Banques de données
ClinicalTrials.gov
['NCT03306394']
Types de publication
Clinical Trial, Phase III
Journal Article
Multicenter Study
Randomized Controlled Trial
Langues
eng
Sous-ensembles de citation
IM
Pagination
2315-2324Subventions
Organisme : Servier, Italy